Skip to content

Released Mar 11, 2026, after the close

10-K filed Mar 11, 2026, 70 days after period end · 0001628280-26-016814

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$9.25Mderived+223.8% vs Q4 2024+13.4% vs Q3 2025
Net Income-$21.66MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$23,878,000N/M
Operating Cash Flowderived-$22,271,000N/M
Free Cash Flowderived-$22,271,000N/M
Margins · derived
Operating margin-258.2%+582.3 pt vs Q4 2024
Net margin-234.3%+448.6 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$9.25M$2.86M$5.77M$4.18M
Net Income-$21.66M-$19.50M-$24.11M-$28.89M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR